BioLineRx Ltd.
BLRX
$2.72
-$0.22-7.48%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -19.92M | -30.12M | -49.15M | -60.61M | -52.46M |
| Total Depreciation and Amortization | 2.86M | 2.24M | 1.96M | 1.33M | 865.00K |
| Total Amortization of Deferred Charges | 59.00K | 59.00K | 59.00K | 59.00K | 0.00 |
| Total Other Non-Cash Items | -6.57M | -429.00K | 14.27M | 21.42M | 16.56M |
| Change in Net Operating Assets | -6.70M | -2.10M | 4.16M | 15.20M | 1.76M |
| Cash from Operations | -30.27M | -30.35M | -28.70M | -22.61M | -33.28M |
| Capital Expenditure | -75.00K | -76.00K | -116.00K | -116.00K | -157.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -2.10M | -8.18M | 11.61M | 1.56M | 25.86M |
| Cash from Investing | -2.18M | -8.26M | 11.49M | 1.44M | 25.70M |
| Total Debt Issued | 19.22M | 19.22M | -- | -- | -556.00K |
| Total Debt Repaid | -3.70M | -3.61M | -2.83M | -1.99M | -1.22M |
| Issuance of Common Stock | 18.17M | 22.61M | 17.04M | 17.04M | 4.44M |
| Repurchase of Common Stock | -180.00K | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 33.51M | 38.22M | 14.21M | 15.06M | 2.67M |
| Foreign Exchange rate Adjustments | 52.00K | -101.00K | -75.00K | -224.00K | -466.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.11M | -481.00K | -3.08M | -6.33M | -5.38M |
